We were able to break down thirty available financial ratios for Oncolytics Biotech, which can be compared to its competitors. The stock experiences a moderate downward daily trend and can be a good diversifier. Check odds of Oncolytics Biotech to be traded at C$1.1956 in 90 days. Key indicators impacting Oncolytics Biotech's financial strength include:
Oncolytics Biotech competes with JPMorgan Chase, Bank of America, Toronto Dominion, Royal Bank, and Royal Bank. Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada. ONCOLYTICS BIOTECH operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange.
Foreign Associate
Germany
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
You should never invest in Oncolytics Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Oncolytics Stock, because this is throwing your money away. Analyzing the key information contained in Oncolytics Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Oncolytics Biotech Key Financial Ratios
Oncolytics Biotech's financial ratios allow both analysts and investors to convert raw data from Oncolytics Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of Oncolytics Biotech over time and compare it to other companies across industries.
Comparative valuation techniques use various fundamental indicators to help in determining Oncolytics Biotech's current stock value. Our valuation model uses many indicators to compare Oncolytics Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncolytics Biotech competition to find correlations between indicators driving Oncolytics Biotech's intrinsic value. More Info.
Oncolytics Biotech is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, Oncolytics Biotech's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Oncolytics Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oncolytics Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.
Oncolytics Biotech Systematic Risk
Oncolytics Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Oncolytics Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-two with a total number of output elements of nineteen. The Beta measures systematic risk based on how returns on Oncolytics Biotech correlated with the market. If Beta is less than 0 Oncolytics Biotech generally moves in the opposite direction as compared to the market. If Oncolytics Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Oncolytics Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Oncolytics Biotech is generally in the same direction as the market. If Beta > 1 Oncolytics Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Oncolytics Biotech Total Assets Over Time
Oncolytics Biotech Thematic Clasifications
Oncolytics Biotech is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
Today, most investors in Oncolytics Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Oncolytics Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Oncolytics Biotech growth as a starting point in their analysis.
Oncolytics Biotech December 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Oncolytics Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Oncolytics Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Oncolytics Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Oncolytics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Oncolytics Biotech's daily price indicators and compare them against related drivers.
When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.